TrialFrontiers in immunology2021

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.

Ping Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.